Personalizing arthritis treatment: genes may predict drug success
NCT ID NCT07388407
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how genetic differences influence the effectiveness and side effects of leflunomide, a common rheumatoid arthritis drug. Researchers will recruit 110 Pakistani patients starting leflunomide and track their disease activity and side effects over six months. By analyzing DNA from blood samples, they hope to find genetic markers that predict who responds well and who experiences toxicity, potentially leading to more personalized treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
leflunomide
What this could lead to
If successful, this could help doctors predict which rheumatoid arthritis patients will benefit most from leflunomide and who might have side effects.
What could go wrong
This is an early observational study with only 110 participants. Results may not apply to all populations, and the genetic markers found may not reliably predict outcomes in practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fauji Foundation Hospital, Rawalpindi
RECRUITINGRawalpindi, Punjab Province, 46000, Pakistan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shifa International Hospital
COMPLETEDIslamabad, Punjab Province, 44000, Pakistan